WHO issued two statements addressing concerns about the use of progestogen-only implants and depot-medroxyprogesterone acetate (DMPA). The statements recommended no restrictions on the use of hormonal contraceptives, including DMPA for women at high risk of HIV (MEC Category 1) and that women and couples at high risk of HIV acquisition should be informed about and have access to HIV preventive measures.
WHO statement on Progestogen-only implants